Business Context and Reporting Period
This Form 8-K Current Report was filed by DarioHealth Corp. on February 14, 2020, regarding an event that occurred on February 12, 2020. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbols DRIO (Common Stock) and DRIOW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation matters.
Material Changes
The material change reported is the extension of the Chief Executive Officer's employment agreement. On February 12, 2020, the Compensation Committee of the Board of Directors approved a two-year extension of the existing agreement for CEO Erez Raphael, extending its term through December 31, 2022.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document is limited to the disclosure of the executive compensation arrangement under Item 5.02.
Investor Verification Checklist
- Verify the specific terms and compensation details of the extended employment agreement for CEO Erez Raphael, which are not detailed in this summary.
- Confirm the exact expiration date of the agreement is December 31, 2022.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K does not contain financial metrics.